金融界消息 截至2025年8月22日收盘，人福医药（600079）报收于20.92元，上涨0.77%，换手率 1.87%，成交量28.83万手，成交金额6.02亿元。 资金流向方面，今日主力资金净流入3117.88万元，占比成交额5.18%。其中，超大单净流入2890.18万 元、占成交额4.8%，大单净流入227.70万元、占成交额0.38%，中单净流出流出5109.08万元、占成交额 8.49%，小单净流入1991.19万元、占成交额3.31%。 天眼查商业履历信息显示，人福医药集团股份公司，成立于1993年，位于武汉市，是一家以从事医药制 造业为主的企业。企业注册资本163222.5965万人民币，实缴资本38700万人民币。公司法定代表人为杜 文涛。 通过天眼查大数据分析，人福医药集团股份公司共对外投资了48家企业，参与招投标项目18次，知识产 权方面有商标信息364条，专利信息266条，此外企业还拥有行政许可14个。 来源：金融界 人福医药最新一期业绩显示，截至2025一季报，公司营业总收入61.37亿元、同比减少3.61%，归属净利 润5.40亿元，同比增长11.09%，扣非净利润5.31亿元，同 ...

Market Overview - The Shanghai Composite Index closed at 3825.76 points, above the annual line, with an increase of 1.45% [1] - The total trading volume of A-shares reached 25,788.42 billion yuan [1] Stocks Breaking Annual Line - A total of 24 A-shares have surpassed the annual line today, with notable stocks including NovaStar, Nasda, and Zhaoshengwei, showing significant deviation rates of 7.19%, 4.59%, and 4.07% respectively [1] - Stocks with smaller deviation rates that just crossed the annual line include China National Materials, Kweichow Moutai, and Ruisi Kanda [1] Top Stocks by Deviation Rate - The top three stocks with the highest deviation rates are: - NovaStar (7.19% deviation, latest price 174.84 yuan) [1] - Nasda (4.59% deviation, latest price 26.55 yuan) [1] - Zhaoshengwei (4.07% deviation, latest price 84.73 yuan) [1] Additional Notable Stocks - Other notable stocks with significant performance include: - Jin Yu Medical (3.28% deviation, latest price 31.57 yuan) [1] - China Merchants Heavy Industry (3.08% deviation, latest price 6.59 yuan) [1] - BOE Technology Group (2.18% deviation, latest price 4.18 yuan) [1]

Core Points - The Shanghai Composite Index closed at 3796.36 points, above the annual line, with a change of 0.67% [1] - The total trading volume of A-shares reached 15,306.58 billion yuan [1] - Thirteen A-shares have broken through the annual line today, with notable divergence rates for stocks like Nova Star Cloud, China Merchants Energy, and Zhaosheng Microelectronics [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3796.36 points, reflecting a 0.67% increase [1] - Total A-share trading volume is reported at 15,306.58 billion yuan [1] Stocks Breaking Through Annual Line - Notable stocks that have surpassed the annual line include: - Nova Star Cloud (Code: 301589) with a divergence rate of 8.66% and a daily increase of 10.32% [1] - China Merchants Energy (Code: 601872) with a divergence rate of 2.92% and a daily increase of 5.96% [1] - Zhaosheng Microelectronics (Code: 300782) with a divergence rate of 2.43% and a daily increase of 4.21% [1] Additional Stocks with Minor Divergence - Other stocks that have recently crossed the annual line with smaller divergence rates include: - Wanli Stone (Code: 002785) with a divergence rate of 1.20% [1] - Wanhua Chemical (Code: 600309) with a divergence rate of 1.18% [1] - Weisheng Information (Code: 688100) with a divergence rate of 1.11% [1] - Others include Tongwei Co., Newpoint Software, Renfu Pharmaceutical, and Yilian Network with minor divergence rates [1]

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index above the annual line, indicating a potential bullish trend in the market [1] Group 1: Market Performance - As of 10:31 AM today, the Shanghai Composite Index is at 3784.84 points, with a change of 0.36% [1] - The total trading volume of A-shares today is 1,091.82 billion yuan [1] Group 2: Stocks Breaking Annual Line - Thirteen A-shares have surpassed the annual line today, with notable stocks including Nova Star Cloud, Zhaosheng Micro, and China Merchants Energy, showing significant deviation rates of 7.63%, 3.61%, and 2.46% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Wanhua Chemical, Ruisi Kanda, and Renfu Pharmaceutical [1] Group 3: Individual Stock Performance - Nova Star Cloud (301589) has a daily increase of 9.27% and a trading turnover rate of 5.25%, with a latest price of 175.57 yuan and a deviation rate of 7.63% [1] - Zhaosheng Micro (300782) increased by 5.42% with a turnover rate of 3.90%, latest price at 84.36 yuan and a deviation rate of 3.61% [1] - China Merchants Energy (601872) rose by 5.48%, with a turnover rate of 1.84%, latest price at 6.55 yuan and a deviation rate of 2.46% [1]

Market Overview - The Shanghai Composite Index is at 3781.13 points, above the annual line, with a change of 0.40% [1] - The total trading volume of A-shares is 1,193.158 billion yuan [1] Stocks Breaking Annual Line - A total of 31 A-shares have surpassed the annual line today, with notable stocks including Meihua Medical, *ST Aowei, and Pianzaihuang, showing divergence rates of 14.13%, 2.94%, and 2.77% respectively [1] - Stocks with smaller divergence rates that have just crossed the annual line include China Wuyi, Huilun Crystal, and Zhuoshengwei [1] Top Stocks by Divergence Rate - Meihua Medical (301363) has a significant increase of 17.30% with a turnover rate of 23.04% and a divergence rate of 14.13% [1] - *ST Aowei (002231) increased by 3.12% with a turnover rate of 7.79% and a divergence rate of 2.94% [1] - Pianzaihuang (600436) rose by 3.70% with a turnover rate of 1.03% and a divergence rate of 2.77% [1] Additional Notable Stocks - Tongrentang (600085) increased by 1.93% with a divergence rate of 1.77% [1] - Maire Medical (300760) rose by 3.40% with a divergence rate of 1.53% [1] - Other stocks with minor divergence rates include Aima Technology (603529) and China Railway Construction (601186) with divergence rates of 1.06% and 0.96% respectively [1]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the transformation of China's medical insurance system from a "single basic coverage" model to a "basic insurance + commercial insurance supplementary" dual-track system, marked by the introduction of the commercial insurance innovative drug directory [5][13] - The commercial insurance innovative drug directory primarily focuses on high-value innovative drugs in oncology, immunology, and rare diseases, providing a new pathway for these drugs to gain market access [6][20] - The report indicates that the inclusion of innovative drugs in both the basic and commercial insurance directories is expected to lead to rapid revenue growth for related companies, benefiting patients and driving growth for innovative pharmaceutical firms [6][29] Summary by Sections Section 1: National Drug Review and Commercial Insurance Directory - The announcement of the national drug review results and the debut of the commercial insurance innovative drug directory occurred on August 12, 2025, indicating a significant policy shift [5][13] - The commercial insurance directory includes 121 drugs, focusing on those with high clinical value and significant patient benefits, particularly in oncology and rare diseases [20][27] - The report emphasizes that the commercial insurance directory allows for a more flexible pricing mechanism, which does not count towards hospital drug expenditure ratios, thus facilitating the market entry of high-value innovative drugs [28][24] Section 2: Market Performance and Trends - In August 2025, the pharmaceutical and biotechnology sector saw a 3.08% increase, outperforming the CSI 300 index by 0.7 percentage points [2][10] - The medical research outsourcing sector experienced the highest growth, while the offline pharmacy sector faced declines [10][12] - The report notes that the inclusion of over 20 traditional Chinese medicines in the 2025 basic medical insurance directory, primarily unique products, reflects a growing recognition of traditional medicine [6][29] Section 3: Recommended Stocks and Beneficiaries - Recommended stocks in the pharmaceutical and biotechnology sector include companies such as Heng Rui Medicine, East China Medicine, and Innovent Biologics, among others [7] - The report also highlights potential beneficiaries in the CXO sector, including WuXi AppTec and Tigermed, as well as companies in the medical device and service sectors [7][29]

截至8月14日收盘，芬太尼概念上涨1.24%，位居概念板块涨幅第2，板块内，1股上涨，博拓生物20%涨 停，跌幅居前的有人福医药、东方生物、国药现代等，分别下跌3.16%、2.59%、1.23%。 （文章来源：证券时报网） | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 688767 | 博拓生 物 | 19.99 | 6.99 | 5164.59 | 11.85 | | 300482 | 万孚生 物 | -0.90 | 3.77 | 2006.03 | 5.04 | | 600079 | 人福医 药 | -3.16 | 2.37 | 629.48 | 0.80 | | 688298 | 东方生 物 | -2.59 | 1.62 | 545.83 | 5.85 | | 600511 | 国药股 份 | -0.64 | 0.90 | -26.01 | -0.18 | | 002262 | 恩华药 业 | -0.59 | 1 ...

金融界消息 截至2025年8月14日收盘，人福医药（600079）报收于21.13元，下跌3.16%，换手率 2.37%，成交量36.55万手，成交金额7.84亿元。 资金流向方面，今日主力资金净流入2255.45万元，占比成交额2.88%。其中，超大单净流入2093.88万 元、占成交额2.67%，大单净流入161.57万元、占成交额0.21%，中单净流出流出3769.42万元、占成交 额4.81%，小单净流入1513.97万元、占成交额1.93%。 人福医药最新一期业绩显示，截至2025一季报，公司营业总收入61.37亿元、同比减少3.61%，归属净利 润5.40亿元，同比增长11.09%，扣非净利润5.31亿元，同比增长14.35%，流动比率1.494、速动比率 1.239、资产负债率42.59%。 天眼查商业履历信息显示，人福医药集团股份公司，成立于1993年，位于武汉市，是一家以从事医药制 造业为主的企业。企业注册资本163222.5965万人民币，实缴资本38700万人民币。公司法定代表人为周 汉生。 通过天眼查大数据分析，人福医药集团股份公司共对外投资了49家企业，参与招投标项目18次，知识产 ...

这笔分红对当代科技而言，犹如杯水车薪——其公开债务规模已达数十亿，但在司法重整程序启动后，这笔资金流向却成谜。有市场分析指出， 当代科技通过信托计划持有股份的表决权虽已委托给招商系，但财产权仍归属自身，这意味着分红资金可直接进入原股东账户。在股权被14轮司 法轮候冻结的背景下，这笔"漏网之鱼"的流向，难免让人联想至规避债务清偿的灰色操作。 高分红的代价已开始显现。2024年末，人福医药货币资金较上年减少18%，经营活动现金流净额同比下降23%，而短期借款与一年内到期的非流 动负债合计达67亿元，较2022年增长41%。这种"拆东墙补西墙"的分红模式，本质上是以牺牲公司流动性为代价，为原股东的债务困局输血。 司法冻结下的控制权迷阵 招商局集团以118亿元代价拿下26.62%表决权的交易，被媒体渲染为"干净利落的资本接管"，但股权冻结的现实却暴露了这场交易的不彻底性。截 至2025年8月，人福医药已发布28次与当代科技相关的股权冻结公告，这一数字创下A股市场纪录，部分冻结期限甚至延长至2028年，意味着未来 三年公司股权稳定性仍将受到持续冲击。 当招商局集团的红色印章落在 人福医药 股权转让 协议上时，这家深陷债 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次利润分配方案经人福医药集团股份公司（以下简称"人福医药"或"公司"）2025年6月20日的2024年 年度股东会审议通过。 二、分配方案 1.发放年度：2024年年度 ■ 四、分配实施办法 1.实施办法 除公司自行发放的对象外，其余股东的现金红利公司委托中国结算上海分公司通过其资金清算系统向股 权登记日上海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办 理指定交易的投资者可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利 暂由中国结算上海分公司保管，待办理指定交易后再进行派发。 2.自行发放对象 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本1,632,225,965股为基数，每股派发现金红利0.32元（含税）， 共计派发现金红利522,312 ...